quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

HP outlines $2.8B–$3B free cash flow target for 2026 amid memory cost headwinds and AI PC momentum

View original at seekingalpha.com
HP outlines $2.8B–$3B free cash flow target for 2026 amid memory cost headwinds and AI PC momentum Earnings Call Insights: HP Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Board's priority is to identify the right leader to guide HP through its next phase of evolution

    80% confidence
  • Print share gains achieved and OpEx expected to be flat for FY '26, with ongoing cost-saving efforts

    80% confidence
  • Demand resilience driven by Windows 11 and AI PCs, with growth opportunities in peripherals following refresh cycles

    80% confidence
  • OpenAI partnership puts HP at the forefront of enterprise AI deployments

    80% confidence
  • CEO search involves a broad candidate pool

    80% confidence
  • We have included a significant increase in memory costs in our guidance. We have seen memory costs increase roughly 100% sequentially, and we do forecast that to further increase as we move into the fiscal year.

    80% confidence
  • We did have some memory cost increases in Q1, but it was roughly in line with what we had outlined at the beginning of the year. The increases are more going forward.

    80% confidence
  • PS margins expected to be below the long-term range for the remainder of the year

    80% confidence
  • HP has secured long-term agreements covering memory requirements for fiscal '26, qualified new suppliers, and accelerated product configuration changes

    80% confidence
  • Print operating margins for both Q2 and the full year expected to be near the top end of the long-term range

    80% confidence
  • We did see a moderate amount of customer demand pull-in in the quarter, particularly in Consumer

    80% confidence
  • We are pleased with our first quarter results and the solid progress we made on delivering against our financial commitments. We drove better-than-expected top line growth, fueled by continued refresh momentum in Personal Systems and in our key growth areas.

    80% confidence
  • HP projects PC unit TAM to decline double digits in 2026

    80% confidence
  • Memory costs represent 35% of the PC BOM

    80% confidence
  • We recognize that the environment remains fluid, and we are pulling every lever available to offset these unprecedented headwinds

    80% confidence
  • HP does not anticipate negative impacts from recent U.S. Supreme Court tariff-related rulings

    80% confidence
  • We returned over $600 million to shareholders just in our first quarter and confirmed continued commitment to returning 100% of free cash flow to shareholders

    80% confidence
  • HP is positioned to expand market share and ensure pricing reflects value delivered, especially navigating near-term challenges

    80% confidence

Data points we hold from this source

HP Inc. · memory cost increase sequential100 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
HP outlines $2.8B–$3B free cash flow target for 2026 amid memory cost headwinds and AI PC momentum — Source | Via News | pt.VIA.NEWS